News
LJUIF
0.540
NaN%
--
SSY Group Revamps Board as Veteran Executive Wu Hengyao Joins, Su Xuejun Steps Down
TipRanks · 1d ago
SSY Group Sets Out Board Composition and Committee Roles
TipRanks · 1d ago
SSY Group Wins China Approval for New Antipsychotic Bulk Drug
TipRanks · 09/16 09:12
SSY Group Wins China Approval for New Letermovir Injection
TipRanks · 09/10 04:07
SSY Group Buys 1 Million Shares for Employee Award Scheme
TipRanks · 09/03 09:07
SSY Group Boosts Staff Incentive Pool With Open-Market Share Purchase
TipRanks · 09/02 09:08
SSY Group Wins Key Approval for Diltiazem Cardiovascular Portfolio in China
TipRanks · 09/02 09:07
SSY Group Expands Restricted Share Award Scheme with Market Buyback
TipRanks · 09/01 09:38
SSY Group Boosts Restricted Share Pool With Market Buyback for Incentive Scheme
TipRanks · 08/31 09:55
Huatai Securities Sticks to Their Buy Rating for SSY Group (LJUIF)
TipRanks · 08/29 05:18
SSY Group Wins China Approvals for Two Key Diagnostic Injectables
TipRanks · 08/27 11:10
SSY Group Delivers Profit Growth and Higher Dividend Amid Sector Reforms
TipRanks · 08/26 04:08
SSY Group Declares Interim Cash Dividend for First Half of 2026
TipRanks · 08/26 04:07
SSY Group Secures Approval for New Ozagrel Injection to Bolster Neurology Portfolio
TipRanks · 08/25 09:10
SSY Group Wins China Approval for Vitamin K1 Injection
TipRanks · 08/20 04:42
SSY Group Sets Board Meeting to Approve Interim Results and Consider Dividend
TipRanks · 08/14 08:47
SSY Group Wins China Approval for New Antipsychotic Bulk Drug
TipRanks · 08/07 11:15
SSY Group Wins NMPA Approvals for Four New Drugs, Bolsters Ophthalmic and ICU Portfolios
TipRanks · 08/06 08:47
SSY Group Wins Full Slate of Bids in China’s 12th National Drug Procurement Round
TipRanks · 08/03 10:11
SSY Group Wins NMPA Approval for New Gastrointestinal and Respiratory Drugs
TipRanks · 07/30 08:40
More
Webull provides a variety of real-time LJUIF stock news. You can receive the latest news about Ssy Group through multiple platforms. This information may help you make smarter investment decisions.
About LJUIF
SSY Group Ltd, formerly known as Lijun International Pharmaceutical Holding Co Ltd, is an investment holding company principally engaged in the research, development, manufacture and sale of pharmaceutical products. The Company’s main products include finished medicines of mainly intravenous infusion solution to hospitals and distributors, bulk pharmaceuticals and medical materials. The Company’s products mainly include non-PVC (Polyvinyl chloride) soft bag infusion solution, PP (Polypropylene) plastic bottle infusion solution and Glass bottle infusion solution. The Company’s products also include Hydrochloride Betahistine, Hydrochloride Ambroxol and Doxofylline as well as bulk pharmaceuticals including caffeine, theophylline, aminophylline, metronidazole and nifedipine.